Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.


READ STATEMENTS


this weeks' publications on covid-19 & psoriasis

Rapid online surveys may help illuminate patient perspectives about the SARS-COV-2 virus and the COVID-19 pandemic, allowing clinicians to address these concerns.(1) To understand patient perspectives during the early phases of the COVID-19 pandemic, the National Psoriasis Foundation (NPF) conducted a two-wave survey of a random stratified sample of individuals 18 years of age or older with psoriatic disease in the United States who recently contacted the NPF.
No abstract
No abstract
No abstract
CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

VIEW ALL ON PUBMED

resources from our industry partners

 AbbVie
Amgen
Novartis
UCB

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK